Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients-Reference-Cited by-同舟云学术

Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients

Published:2023-06 Issue: Volume:69 Page:323-329
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Gentile Damiano^ORCID,Sagona Andrea,De Carlo Camilla,Fernandes Bethania,Barbieri Erika,Di Maria Grimaldi Simone,Jacobs Flavia,Vatteroni Giulia,Scardina Lorenzo,Biondi Ersilia,Vinci Valeriano,Trimboli Rubina Manuela,Bernardi Daniela,Tinterri Corrado

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference34 articles.

1. Breast cancer statistics in the European Union: incidence and survival across european countries;Dafni;Breast Care,2019

2. A history of cancer chemotherapy;DeVita;Cancer Res,2008

3. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

4. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response;Rajan;Cancer,2004

5. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;Von Minckwitz;J Clin Oncol,2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated Risk of Adverse Prognosis in Patients with T2-3 Stage Breast Cancer Exhibiting Non-Pathological Complete Response Following Neoadjuvant Chemotherapy: Significance of Regenerating Islet-Derived Family Member 4;Breast Cancer: Targets and Therapy;2024-09

2. The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer—A Systematic Review and Meta-Analysis;Current Oncology;2024-08-03

3. Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Tissue;The Journal of Molecular Diagnostics;2024-07

4. Breast Cancer Patient’s Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II–III Disease;Cancers;2024-06-30

5. Contemporary Approaches to Immunotherapy of Solid Tumors;Cancers;2024-06-19